with us
together we’re making a difference

News Releases

May 24, 2023 |

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

May 16, 2023 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2023 |

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

Apr 11, 2023 |

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Mar 06, 2023 |

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Feb 27, 2023 |

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

Feb 16, 2023 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Jan 17, 2023 |

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Jan 08, 2023 |

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Jan 06, 2023 |

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
Displaying 1 - 10 of 11
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2023 Annexon Inc. All rights reserved.